Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus postoperative adjuvant chemotherapy versus placebo plus postoperative adjuvant chemotherapy after curative gastrectomy for gastric or gastroesophageal junction adenocarcinoma
CTR20212739Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Feb 2022; status: active.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20212739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212739.